Clinical Report: Psilocybin services face real-world test
Overview
State-regulated psilocybin services in Oregon demonstrated reductions in moderate-to-severe depression, anxiety, and PTSD symptoms over three months. Serious behavioral adverse reactions occurred in 1% of participants.
Background
The Oregon Psilocybin Services initiative represents the first regulated system for legal psilocybin use in the United States. This study provides insights into the real-world application of psilocybin services.
Data Highlights
| Condition | Baseline | 1 Month | 3 Months |
|---|---|---|---|
| Moderate-to-severe depression | 42% | 11% | 17% |
| Moderate-to-severe anxiety | 45% | 12% | 13% |
| Moderate-to-severe PTSD | 48% | 19% | 17% |
| Satisfaction with life | 63% | 83% | 82% |
Key Findings
- Moderate-to-severe depression symptoms decreased from 42% at baseline to 11% at 1 month and 17% at 3 months.
- Moderate-to-severe anxiety symptoms decreased from 45% at baseline to 12% at 1 month and 13% at 3 months.
- Moderate-to-severe PTSD symptoms decreased from 48% at baseline to 19% at 1 month and 17% at 3 months.
- 56% of participants reported lifetime psychedelic use, excluding microdosing.
- 4 participants (1%) experienced serious behavioral adverse reactions, all of whom were psychedelic-naive.
- Follow-up rates were 93% at 1 week, 93% at 1 month, and 90% at 3 months.
Clinical Implications
Clinicians should be aware of the potential for serious behavioral adverse reactions, particularly in psychedelic-naive individuals.
Conclusion
The study reports reductions in symptoms of depression, anxiety, and PTSD, while noting the occurrence of serious behavioral adverse reactions.
Related Resources & Content
- Korthuis PT, et al., JAMA Network Open, 2026 -- Safety and Mental Health Outcomes of Oregon State-Regulated Psilocybin Services
- Frontiers in Psychiatry, 2026 -- Inaugural year of regulated psilocybin services in Oregon: safety, motivations, and utilization
- MDSpire News, 2026 -- Psilocybin Trial in Treatment-Resistant Depression Shows Mixed Results
- the analytical scientist — Mushroom for Improvement
- the asco post — Psilocybin-Based Therapy May Address Mental Health Issues in Patients With Cancer, Addiction
- Oregon Health Authority: Oregon Psilocybin Services - What are Psilocybin Services?
- American Psychiatric Association Responds to Executive Order on Accelerating Medical Treatments for Psychedelics
- VA/DoD 2023 Clinical Practice Guideline for the Management of PTSD
- Short-Term and Late-Term Effects of Psilocybin on Symptoms in Major Depression: A Randomized Clinical Trial | Complementary and Alternative Medicine | JAMA Network Open | JAMA Network
- Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression: The EPISODE Randomized Clinical Trial | Trials | JAMA Psychiatry | JAMA Network
- Psilocybin-assisted therapy for treatment-resistant major depressive disorder in a public healthcare setting: a randomized controlled trial | Nature Medicine
- Methodological moderators of psilocybin-assisted therapy in depression: A systematic review and meta-analysis - PubMed
- Safety and Mental Health Outcomes of Oregon State-Regulated Psilocybin Services | Public Health | JAMA Network Open | JAMA Network
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
